Sulfonic, phosphonic or phosphiniic acid .beta..sub.3 agonist derivatives
US5491134A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 16, 1994 |
| Grant date | Feb 13, 1996 |
| Priority date | — |
| Expiry date | Sep 16, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/4006
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: A is a bond or --OCH.sub.2 --, where the oxygen is linked to R.sup.1 ; PA1 B is --CH.sub.2 -- or when R.sup.3 is hydrogen, B may be --CH.sub.2 O-- where the oxygen is linked to the phenyl ring; PA1 R.sup.1 is an aryl group; PA1 R.sup.2 is hydrogen or lower alkyl; PA1 R.sup.3 is hydrogen; or R.sup.2 and R.sup.3 together form the group --CH.sub.2 CH.sub.2 --; and PA1 R.sup.4 is --SO.sub.3 H, --P(O.sub.2 H)R.sup.5, --P(O.sub.2 R.sup.5')R.sup.5, --PO.sub.3 H.sub.2, --PO.sub.3 HR.sup.5' or --PO.sub.3 (R.sup.5').sub.2 where R.sup.5 and R.sup.5' are independently lower alkyl. These compounds are beta.sub.3 adrenergic receptor agonists and are useful, for example, in the treatment of diabetes, obesity, achalasia, and gastrointestinal diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.